Tofersen
(Redirected from Qalsody)
Tofersen
Tofersen is an investigational antisense oligonucleotide designed to treat amyotrophic lateral sclerosis (ALS) associated with mutations in the superoxide dismutase 1 (SOD1) gene. It is a synthetic molecule that targets the mRNA of the SOD1 gene, aiming to reduce the production of the mutant SOD1 protein, which is implicated in the pathogenesis of ALS.
Mechanism of Action
Tofersen works by binding to the mRNA of the SOD1 gene, which is responsible for encoding the SOD1 protein. By binding to this mRNA, Tofersen promotes its degradation through the recruitment of RNase H, an enzyme that cleaves the RNA strand of RNA-DNA hybrids. This process reduces the levels of SOD1 protein, particularly the mutant forms that are toxic to motor neurons.
Clinical Development
Tofersen is currently undergoing clinical trials to evaluate its safety and efficacy in patients with SOD1-ALS. The trials are designed to assess the drug's ability to slow the progression of ALS symptoms and improve motor function. Initial studies have shown promise, with some patients experiencing stabilization of their condition.
Administration
Tofersen is administered via intrathecal injection, which involves delivering the drug directly into the cerebrospinal fluid (CSF) surrounding the spinal cord. This method of administration is chosen to ensure that the drug reaches the central nervous system, where it can exert its effects on motor neurons.
Potential Side Effects
As with any investigational drug, Tofersen may have side effects. Commonly reported side effects include headache, back pain, and procedural pain associated with the intrathecal injection. More serious side effects are being monitored in clinical trials to ensure patient safety.
Future Directions
Research is ongoing to determine the long-term efficacy and safety of Tofersen in treating SOD1-ALS. Additionally, studies are being conducted to explore the potential of antisense oligonucleotides in treating other forms of ALS and neurodegenerative diseases.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Deepika vegiraju, Prab R. Tumpati, MD